<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111409</url>
  </required_header>
  <id_info>
    <org_study_id>300-08-013</org_study_id>
    <nct_id>NCT01111409</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Evaluate the Clinical Effectiveness and Safety of the VFIX Device as Treatment for Apical Prolapse</brief_title>
  <official_title>A Prospective, Multi-Centre Pilot Study to Evaluate the Clinical Effectiveness and Safety of the VFIX Device as Treatment for Apical Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ethicon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ethicon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pilot study is to evaluate the safety and effectiveness of the&#xD;
      VFIX device in maintaining vaginal apical support for at least 6 months in women with&#xD;
      symptomatic apical prolapse (upper vaginal or uterine prolapse).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assuming success of the VFIX anatomical observational study (protocol 300-08-009), in this&#xD;
      pilot study approximately 20 subjects (excluding the Device Run-In (DRI) subjects) will&#xD;
      undergo the VFIX procedure to evaluate the safety and effectiveness of the VFIX device in&#xD;
      maintaining apical support for at least 6 months, in women with symptomatic apical prolapse.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>VFIX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VFIX Device</intervention_name>
    <description>Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor</description>
    <arm_group_label>VFIX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  Subjects of child bearing potential have a negative blood or urine pregnancy test&#xD;
             prior to the procedure and subject has completed childbearing&#xD;
&#xD;
          -  Subject with apical prolapse at stage II or more and requiring treatment (C should be&#xD;
             at least -1 cm)&#xD;
&#xD;
          -  On reduction of the apical prolapse, leading edge of prolapse should be at or above&#xD;
             the hymen&#xD;
&#xD;
          -  If applicable, subject has small/normal size uterus and there is no elongation of the&#xD;
             cervix as determined by clinical assessment&#xD;
&#xD;
          -  The vaginal apex can reach the Sacrospinous Ligament (SSL) on exam&#xD;
&#xD;
          -  Subjects are allowed concurrent incontinence procedure as required&#xD;
&#xD;
          -  Concurrent perineal repairs and excision of excess vaginal tissue repairs as required&#xD;
&#xD;
          -  Agrees to participate in the study, including completion of all study-related&#xD;
             procedures, evaluations and questionnaires, and documents this agreement by signing&#xD;
             the Ethics Committee approved informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Additional surgical intervention for POP repairs concurrent to the VFIX procedure&#xD;
             (including, but not limited to sacrocolpopexy, paravaginal repair, colporrhaphy, mesh&#xD;
             repair, etc)&#xD;
&#xD;
          -  Experimental drug or experimental medical device within 3 months prior to the planned&#xD;
             procedure&#xD;
&#xD;
          -  Active genital, urinary or systemic infection at the time of the surgical procedure.&#xD;
             Surgery may be delayed in such subjects until the infection is cleared.&#xD;
&#xD;
          -  Previous hysterectomy within 6 months of scheduled surgery.&#xD;
&#xD;
          -  Coagulation disorder or on therapeutic anticoagulant therapy (except aspirin) at the&#xD;
             time of surgery&#xD;
&#xD;
          -  Nursing or pregnant&#xD;
&#xD;
          -  Presence of cancers of the vagina, cervix, or uterus&#xD;
&#xD;
          -  In the investigator's opinion, any medical condition or psychiatric illness that could&#xD;
             potentially be life threatening or affect their ability to complete the study visits&#xD;
             according to this protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Robinson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ethicon, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QEII Hospital</name>
      <address>
        <city>Brisbane</city>
        <zip>QLD 4108</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frances Perry House</name>
      <address>
        <city>Parkville</city>
        <zip>VIC 3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urogynaecology Unit, Royal Women's Hospital</name>
      <address>
        <city>Parkville</city>
        <zip>VIC 3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>October 10, 2014</last_update_submitted>
  <last_update_submitted_qc>October 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

